GSK and Vir Biotech have teamed up to develop a COVID-19 vaccine and they aim to begin a phase 2 trial in the next three to four months.

Vir’s current product development pipeline targets hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis.